spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

14th Annual Biomarkers Congress

Biomarkers Congress UK 2019

21-22 February 2019
Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.

Biomarkers are a fundamental part of drug development, playing a critical role in drug discovery, preclinical and clinical development, diagnostics and prognostics. Across two days and over 55 presentations, senior experts will provide a comprehensive look at the marketplace to make sure you leave with an increased knowledge of the current trends influencing biomarker research. 

2019 sees the return of our popular discovery, precision medicine and clinical streams designed to provide updates across multiple therapeutic areas, from market-dominating oncology and neuroscience through to more emerging fields such as infectious, cardiovascular and rare diseases. Benefit further from case studies on topical technology innovation in this space: imaging techniques, proteomics and immuno-assays. We are also pleased to announce an additional two streams highlighting important opportunities in the biomarker market: Biomarkers for Early Detection and Prognosis and Digital Biomarkers.

Key Speakers include:

· Mark Fidock, Vice President, AstraZeneca 

· Frank Kramer, Director Biomarker Strategist, Bayer 

· Thomas Hach, Director Healthcare Systems, Novartis 

· Devangi Mehta, Director, Development Biomarkers and Bioanalytical Sciences, Biogen 

· Kay-Gunnar Stubenrauch, Head of Large Molecule Bioanalytical Sciences 1, Roche 

· Joanne Hackett, Chief Commercial Officer, Genomics England

The two day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions – from panels and roundtables through to two workshops on clinical biomarker assay validation and data analytics.  It brings together over 350 senior industry experts and key opinion leaders in biomarkers. For more information about the programme and registration, please contact Angela Fernandez Saez at a.fernandez@oxfordglobal.co.uk

Contact Details: 

General Enquiries: +44 (0) 1865 248455

For speaker opportunities contact j.thomson@oxfordglobal.co.uk
For sponsorship opportunities contact sponsorship@oxfordglobal.co.uk
For information on registration contact marketing@oxfordglobal.co.uk
For press & marketing enquiries contact a.saez@oxfordglobal.co.uk

phone +44 1865 248 455
email marketing@oxfordglobal.co.uk
web https://bit.ly/2zInOAb
email Manchester, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>


News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement